Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-P16-093 vs 18F-FDG PET/CT in ccRCC
NCT05432947Completed
- Sponsor
- Peking Union Medical College Hospital
- Start
- Apr 2022
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of 68Ga-P16-093 in clear cell renal cell carcinoma (ccRCC), sponsored by Peking Union Medical College Hospital. Primary endpoint: Diagnostic performance at 1 year. Started Apr 2022; status: completed.
02
Drugs
68Ga-P16-093
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT05432947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05432947.